Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Discovery offers hope for anti-cancer therapy
Immunoglobulin E (IgE) antibodies are created when the immune system overreacts to an allergen.

Immunoglobulin E antibodies could fight cancer in humans and dogs

Antibodies that are produced in response to allergens could offer hope for a new anti-cancer therapy in dogs and humans, scientists have said.

Immunoglobulin E (IgE) antibodies are created when the immune system overreacts to an allergen, such as pollen. However, their original purpose is to repel harmful external substances.  

A team of international scientists have now developed a ‘canine IgE’ that targets the EGFR growth factor in cancerous tumours. In-vitro studies found that, in more than 60 per cent of cases, the tumour was destroyed by IgE antibodies.

IgE antibodies build a ‘bridge’ between EGFR on cancer cells and inflammatory cells, which releases tumour necrosis factors.

The study, published in the Journal of Allergy and Clinical Immunology, offers hope for humans too, as canine and human EGFR are a 92 per cent match.

Lead author Erika Jensen-Jarolim said: "We can therefore hope that we have made an important contribution towards developing a new form of immunotherapy against cancerous tumours.

"A subsequent clinical trial will be conducted in canine patients to validate the results in an international joint initiative before moving to human trials.”

Image © M. Bernkopf/Vetmeduni Vienna

Become a member or log in to add this story to your CPD history

Equine Disease Surveillance report released for Q4 2025

News Story 1
 The latest Equine Disease Surveillance report has been released, with details on equine disease from Q4 of 2025.

The report, produced by Equine Infectious Disease Surveillance, includes advice on rule changes for equine influenza vaccination.

Statistics and maps detail recent outbreaks of equine herpes virus, equine influenza, equine strangles and equine grass sickness. A series of laboratory reports provides data on virology, bacteriology, parasitology and toxicosis.

This issue also features a case study of orthoflavivus-associated neurological disease in a horse in the UK. 

Click here for more...
News Shorts
RCVS annual renewal fee for vets due

RCVS' annual renewal fee for veterinary surgeons is now due. Vets must pay their renewal fee before Wednesday, 1 April 2026.

This year's standard annual fee has increased to 431 from last year's 418. This is an approximately three per cent increase, as approved by RCVS Council and the Privy Council.

Tshidi Gardner, RCVS treasurer, said: "The small fee increase will be used to help deliver both our everyday activities and our new ambitious Strategic Plan, which includes aims such as achieving new legislation, reviewing the Codes of Professional Conduct and supporting guidance, and continuing to support the professions through activities such as the Mind Matters Initiative, RCVS Academy and career development."

A full breakdown of the new fees is on the RCVS website. Information about tax relief is available on the UK government website.